Changzhou move more forging new pharmaceutical industry chain 
 
 
Source: China science and technology network - journal of science and technology 
 
 
Publisher: Zhang Jian shafts 
 
 
Date: 2015-01-06 

    The new medicine industry has been the changzhou focus on the development of strategic emerging industries. Changzhou recently requested under construction chain, chain, chain thought, to speed up the industrial chain to build, form a reasonable allocation of resources, to support each other, upstream and downstream of good situation closely. Peng-ju jiang, deputy director of changzhou city technology bureau, told reporters that in 2013, changzhou new medicine industry rules of 143 enterprises, output value reached 37.3 billion yuan, chemical medicine and biological pharmaceutical profit tax output ratio reached 22% and 22% respectively, become the industry contribution rate is higher. At present, changzhou new medicine industry has formed several major features:
 
    Industry development features. Gradually from chemicals to drug intermediates, pharmaceutical industry development into active pharmaceutical ingredients and finished products of medicine, biological medicine industry, formed is given priority to with medicine, pesticides, veterinary drugs is complementary, industrial parallel good biological industry development pattern. 41 pharmaceutical production enterprise with the drug registration approval 787, obtain new drug certificate, 65 copies. Medical device manufacturing enterprise with 298 device registration certificate to nearly 1300.
 
    Subdivision industry have an impact. The chemical medicine sector, has gathered represented by medicine, SiYao, fangyuan often more than 30 key enterprises. 2013 output value 5.62 billion yuan, sales income 5.42 billion yuan, profit tax of 1.23 billion yuan, tax turnover year-on-year growth of 43%. Backbone enterprise fangyuan pharmaceutical research and development of new drugs for m star, its API production accounted for 80% of the market. Biological medicine plate, offer the red biochemical, first sound WeiKe in thousands, dichroa biochemical and other key enterprises. 2013 output value 1.05 billion yuan, sales income 1.01 billion yuan, profit tax of 300 million yuan, tax turnover year-on-year growth of 48%, backbone enterprises thousand red drug heparin to become the largest and the world's third largest supplier. Medical equipment sector, changzhou has become an important production base of global orthopaedic implant devices and disposable medical device manufacturing enterprise agglomeration.
 
    Industrial concentration has a layout. At present, the city's total of biomedical professional incubator, accelerator, industrial park 5, more than 10 offer comprehensive biological medicine enterprise incubator, involving drugs, medical equipment, mobile medical treatment in various fields.
 
    Enterprise development is innovation. Changzhou new pharmaceutical enterprise independent innovation ability significantly increased, in 2013, changzhou in the new medical field 14 received a national science and technology projects, two projects won the national new medicine special support; A project won the national 863 plans to support; A project won the national science and technology support plan.
 
    Merger, acquisition and reorganization into a hot spot. After the first two years, comfort holdings, creation medical history by beauty's power, respectively for the large acquisition, since this year marriage with the world 500 strong covidien medical condi company, once again become the milestone in the field of medical apparatus and instruments.
 
    In the face of changzhou biological medicine industry chain is shorter, chain advantage is not big problem, such as development of changzhou are struggling to find suitable for their own development path. Changzhou zhou, director of the center for biotechnology development is introduced, the next step, changzhou new pharmaceutical industry will be under construction on the chain, chain, chain launch various initiatives, promote the overall development of industry.
 
    Built upstream r&d industry development chain. To promote changzhou university life with pharmaceutical institute, institute of biomedical engineering and health sciences, nanjing university changzhou ability construction, r&d institutions, such as high and new technology research institute and through the industry technology innovation alliance to develop generic technology research and development, through drug r&d outsourcing strategy solving key technical bottlenecks.
 
    Consolidate the advantages of the industrial chain link. Actively develop and expand with characteristic of changzhou chemical pharmaceuticals, in apis and intermediates in the production process, as far as possible to introduce biosynthesis, transformation, separate steps, reduce the pollution and energy consumption, improve product purity and reduce production cost, vigorously promote and advance the biological medicine industrial biological technological upgrading, transformation and upgrading of products to the pharmaceutical preparations at the same time.
 
    Broaden the product line. Medicine, to take advantage of gene engineering, cell engineering and other biochemical technology to develop new biological medicinal products, biochemical and biological product group; Develop high-end pharmaceutical excipients products, expand the scope of indications, drug delivery system change, improve the quality of generic drugs and product value-added, narrow the gap between with the original drug. To develop the characteristics of TCM products, and actively develop Chinese medicine yinpian and plant extracts. Equipment aspect, emphatically introducing stent, implants, repair materials, medical catheter (silk), important organ replacement products, high-end medical packaging material and high-grade medical dressings, medical equipment and operation navigation equipment key spare parts and other technology products.
 
    Improve the downstream distribution chain. In order to strengthen the management of drugs and devices market circulation, strengthen the chain drug stores, the supervision of medical institutions, to speed up the approval, medicine, electricity and other new sales terminal, promote industrial chain upstream and downstream of the collaboration, form a reasonable allocation of resources, to support each other, interdependence of the good situation.